Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results - HEC Paris - École des hautes études commerciales de Paris Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2020

Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results

Résumé

We examine whether a firm’s decision to disclose non-financial proprietary information depends on peer disclosures of similar information. Using a sample of 5,035 unique clinical trials by U.S. pharmaceutical firms over the 2007-2014 period, we find that the firm is less likely to disclose its own clinical trial results if peers have published clinical trial results pertaining to the same medical condition. Conditional on disclosing clinical trial results, the firm is also less likely to disclose the trial results on time when peers have disclosed their clinical trial results. Our cross-sectional tests suggest that proprietary costs of disclosure play an important role in the relation between peer disclosures and the firm’s own disclosure. In particular, the negative relation is more pronounced when proprietary costs of disclosure are higher. Taken together, our findings provide new evidence on the interplay between peer and own disclosures of non-financial proprietary information.

Dates et versions

hal-02896056 , version 1 (10-07-2020)

Identifiants

Citer

Vedran Capkun, Yun Lou, Yin Wang. Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results. 2020. ⟨hal-02896056⟩
69 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More